1. Signaling Pathways
  2. Cell Cycle/DNA Damage
  3. PPAR
  4. PPAR Isoform
  5. PPAR Agonist

PPAR Agonist

PPAR Agonists (47):

Cat. No. Product Name Effect Purity
  • HY-120596
    PPARδ/γ agonist 1 sodium
    Agonist 99.91%
    PPARδ/γ agonist 1 sodium is a chemically unique and brain penetrant dual PPAR delta/gamma agonist.
  • HY-B1415
    Clofibric acid
    Agonist 99.77%
    Clofibric acid (Chlorofibrinic acid), the pharmaceutically active metabolite of lipid regulators Clofibrate, Etofibrate and Etofyllinclofibrate, is a PPARα agonist which exhibits hypolipidemic effects.
  • HY-17444
    Tesaglitazar
    Agonist 98.09%
    Tesaglitazar is a dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist that is more potent on PPARγ than on PPARα, with EC50s of 13.4 μM and 3.6 μM for rat PPARα and human PPARα, respectively, and approximately 0.2 μM for both rat and human PPARγ.
  • HY-W011220
    Ciglitazone
    Agonist 98.89%
    Ciglitazone is a potent and selective PPARγ agonist (EC50=3 μM).
  • HY-14739
    Choline Fenofibrate
    Agonist 99.93%
    Choline Fenofibrate (ABT-335), a choline salt of Fenofibric acid (HY-B0760), releases free Fenofibric acid in the gastrointestinal tract.
  • HY-106278
    GW 590735
    Agonist 98.87%
    GW 590735 is a potent and selective PPARα agonist.
  • HY-N6642
    Ankaflavin
    Agonist
    Ankaflavin, isolated from Monascus-Fermented red rice, is an orally active PPARγ agonist.
  • HY-101676
    RG-12525
    Agonist 98.39%
    RG-12525 is a a specific, competitive and orally effective antagonist of the peptidoleukotrienes, LTC4, LTD4 and LTE4, inhibiting LTC4-, LTD4- and LTE4-inducd guinea pig parenchymal strips contractions, with IC50s of 2.6 nM, 2.5 nM and 7 nM, respectively; RG-12525 is also a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist with IC50 of appr 60 nM and a potent inhibitor of CYP3A4, with a Ki value of 0.5 µM.
  • HY-105074
    Farglitazar
    Agonist
    Farglitazar is a PPARγ agonist that has significant therapeutic benefits such as glycemic control in type 2 diabetic patients.
  • HY-131265
    Mesalamine impurity P
    Agonist
    Mesalamine impurity P is an impurity of Mesalamine (HY-15027).
  • HY-14649S2
    11-cis-Retinoic Acid-d5
    Agonist
  • HY-146439
    PPARγ agonist 4
    Agonist
    PPARγ agonist 4 (Compound 18b) is a potent and selective agonist of PPARγ.
  • HY-B0637S1
    Bezafibrate-d4
    Agonist
  • HY-50935S
    Troglitazone-d4
    Agonist
  • HY-143862
    Pparδ agonist 7
    Agonist
    Pparδ agonist 7 is a potent agonist of Pparδ.
  • HY-143863
    PPARδ agonist 8
    Agonist
    Pparδ agonist 8 is a potent agonist of Pparδ.
  • HY-141793
    ATRA-biotin
    Agonist
    ATRA-biotin (Biotin-ATRA-conjugate) is a biotin-conjugated ATRA.
  • HY-N9333
    Wistin
    Agonist
    Wistin, isolated from Caragana sinica roots, is a PPARα and PPARγ agonist.
  • HY-112597
    Pparδ agonist
    Agonist
    PPARδ agonist is a PPARδ agonist extracted from patent US20180071304, compound example 10.
  • HY-107542S2
    Oleoylethanolamide-d2
    Agonist